Claim Missing Document
Check
Articles

Found 2 Documents
Search

Safety Assessment of Proton-Pump Inhibitors: Study of Cardiovascular Adverse Events Using Global Pharmacovigilance Data Salma Nur Azizah Azzahra; Fita Rahmawati; Agung Endro Nugroho
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 11, No 1 (2026)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v11i1.107840

Abstract

Proton-pump inhibitors (PPIs) have been associated with adverse cardiovascular events, underscoring the need for comprehensive safety evaluation, yet systematic consolidation of data on PPI-related adverse drug reactions (ADRs) leading to cardiovascular events remains lacking. This study aims to descriptively analyze cardiovascular events related to PPI use to summarize their safety profile. A quantitative descriptive analysis was performed on cardiovascular ADRs associated with PPIs using global pharmacovigilance data. The top 25 reported cardiovascular ADRs for each PPI were identified from VigiAccess launched by World Health Organization (WHO) global database. We selected the same 20 set potential ADRs using Venny 2.1.0 to enhance the comparability of data and we summarized by frequency and percentage. A total of 15,263 cardiovascular ADR cases were identified. Omeprazole showed the highest reports, mainly palpitations (1,675 cases; 28.5%), cardiac flutter (759 cases; 12.91%), tachycardia (549 cases; 9.34%), and myocardial infarction (498 cases; 8.47%). Pantoprazole reported palpitations (893 cases; 27.43%), tachycardia (332 cases; 10.20%), and cardiac flutter (326 cases; 10.01%), while lansoprazole (1,782 cases; 11.7%) reported palpitations (451 cases; 25.3%), tachycardia (166 cases; 9.3%), and cardiac flutter (153 cases; 8.6%). Esomeprazole was most associated with myocardial infarction (951 cases; 21.88%), palpitations (621 cases; 14.29%), and cardiac failure congestive (380 cases; 8.74%). PPIs are associated with cardiovascular ADRs such as palpitations and myocardial infarction, emphasizing the importance of careful risk assessment during therapy.
Anti-Inflammatory Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid Derived from Patin Fish Oil on Diabetic Nephropathy: A Bioinformatics Study Doddy Aditya Purnomo; Kevin Awidarta; Agung Endro Nugroho; Abdul Rohman
Journal of Food and Pharmaceutical Sciences Vol 14, No 1 (2026): J.Food.Pharm.Sci
Publisher : Integrated Research and Testing Laboratory (LPPT) Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jfps.22899

Abstract

Diabetic nephropathy is a severe complication of diabetes mellitus with a significant global impact on end-stage renal disease. Fish-derived fatty acids show promise in inflammatory disorders, but their mechanisms in diabetic nephropathy remain unclear. This study used network pharmacology and molecular docking to investigate the therapeutic targets of EPA and DHA from Patin fish oils. Potential targets of EPA and DHA were retrieved from the Swiss Target Prediction, SEA, and SuperPRED databases, identifying 160 and 185 targets, respectively. Notably, 37 and 62 of these targets overlapped with DN-related targets from GeneCards, DisGeNET, and OMIM. Protein-protein interaction (PPI) network analysis revealed hub genes, including PPARG, TLR4, and TP53, as critical mediators. Gene Ontology (GO) enrichment analysis revealed involvement in biological processes such as collagen metabolic process for EPA and regulation of inflammatory response for DHA, while KEGG pathway analysis highlighted the modulation of PPAR signaling, the renin-angiotensin system, and the AGE-RAGE signaling pathway. Molecular docking confirmed favorable binding affinities of EPA and DHA to key targets such as PPARG (-8.04 kcal/mol for DHA) and PPARD (-8.11 kcal/mol for EPA). These findings suggest that EPA and DHA may mitigate DN-associated inflammation through multi-target and multi-pathway interactions, positioning them as potential supplementary therapeutic agents.